Ardelyx Inc
Company Profile
Business description
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Contact
400 Fifth Avenue
Suite 210
WalthamMA02451
USAT: +1 510 745-1700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
395
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,637.80 | 12.90 | 0.15% |
CAC 40 | 7,817.47 | 29.37 | 0.38% |
DAX 40 | 24,048.60 | 10.41 | 0.04% |
Dow JONES (US) | 42,098.70 | 244.95 | -0.58% |
FTSE 100 | 8,742.68 | 16.67 | 0.19% |
HKSE | 23,573.38 | 315.07 | 1.35% |
NASDAQ | 19,100.94 | 98.22 | -0.51% |
Nikkei 225 | 38,432.98 | 710.58 | 1.88% |
NZX 50 Index | 12,281.31 | 80.95 | -0.65% |
S&P 500 | 5,888.55 | 0.00 | 0.00% |
S&P/ASX 200 | 8,409.80 | 12.90 | 0.15% |
SSE Composite Index | 3,363.45 | 23.51 | 0.70% |